<DOC>
	<DOCNO>NCT02954887</DOCNO>
	<brief_summary>This trial consist 3 part : pilot safety phase , pivotal randomize controlled phase , open-label extension phase . The open-label extension phase describe record . All participant receive GWP42003-P .</brief_summary>
	<brief_title>Phase 3 Trial Cannabidiol ( CBD ; GWP42003-P ) Infantile Spasms : Open-label Extension Phase ( GWPCARE7 )</brief_title>
	<detailed_description />
	<mesh_term>Spasm</mesh_term>
	<mesh_term>Spasms , Infantile</mesh_term>
	<criteria>Only participant complete pilot pivotal phase trial may proceed take part openlabel extension phase trial . Key eligibility criterion blind phase follow : Key Participant diagnose IS failed respond adequately follow treatment 1 approve IS therapy . Key Participant currently take take clobazam mammalian target rapamycin ( mTOR ) inhibitor within 2 week prior screen visit . Participant QT interval , correct heart rate Bazett 's formula ( QTcB ) , 460 msec great ECG . Participant 's caregiver currently give give recreational medicinal cannabis , synthetic cannabinoidbased medication , within 1 month prior screen visit . Participant 's caregiver unwilling abstain give participant ( include participant 's mother abstaining , breastfeed ) recreational medicinal cannabis , synthetic cannabinoidbased medication ( study drug ) trial . Participant know suspected hypersensitivity cannabinoids excipients study drug , sesame oil . Participant significantly impair hepatic function screen visit . Participant receive investigational medicinal product part clinical trial within minimum 5 halflives prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GWP42003-P</keyword>
	<keyword>Cannabidiol</keyword>
</DOC>